Tauro-β-muricholic acid-d4 (sodium)

Tauro-β-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].

C[C@@H]([C@]1(CC[C@]2([C@@]3([C@H]([C@H]([C@@]4(C([2H])([C@@H](C([2H])(C[C@@]4([C@]3(CC[C@@]21C)[H])C)[2H])O)[2H])[H])O)O)[H])[H])[H])CCC(NCCS(=O)(O[Na])=O)=O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Sayin SI, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013 Feb 5;17(2):225-35.|[3]Wahlström A, et al. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res. 2017 Feb;58(2):412-419.|[4]Fu T, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019 Feb 21;176(5):1098-1112.e18.